The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study
|
---|---|
Published in |
Frontiers in oncology, September 2021
|
DOI | 10.3389/fonc.2021.736620 |
Pubmed ID | |
Authors |
Hirva Mamdani, Bryan Schneider, Susan M. Perkins, Heather N. Burney, Pashtoon Murtaza Kasi, Laith I. Abushahin, Thomas Birdas, Kenneth Kesler, Tracy M. Watkins, Sunil S. Badve, Milan Radovich, Shadia I. Jalal |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 36% |
Switzerland | 1 | 9% |
Hong Kong | 1 | 9% |
Unknown | 5 | 45% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 64% |
Scientists | 2 | 18% |
Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 15 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 20% |
Student > Ph. D. Student | 2 | 13% |
Student > Doctoral Student | 1 | 7% |
Other | 1 | 7% |
Student > Bachelor | 1 | 7% |
Other | 0 | 0% |
Unknown | 7 | 47% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 20% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
Nursing and Health Professions | 1 | 7% |
Biochemistry, Genetics and Molecular Biology | 1 | 7% |
Unknown | 9 | 60% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2022.
All research outputs
#5,432,899
of 25,392,582 outputs
Outputs from Frontiers in oncology
#1,931
of 22,436 outputs
Outputs of similar age
#114,476
of 435,941 outputs
Outputs of similar age from Frontiers in oncology
#99
of 1,403 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 1,403 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.